Ceftobiprole medocaril

Generic Name: Ceftobiprole medocaril

Brand Names: Zevtera

Drug Type: Small Molecule

Chemical Formula: C_₂₆H_₂₆N_₈O_₁₁S_₂

CAS Number: 376653-43-9

Unique Ingredient Identifier: YXV28V1B07

Background: Ceftobiprole medocaril is a ceftobiprole prodrug.

Associated Conditions: Pneumonia

Associated Therapies: -

Clinical Trials

Late-onset Sepsis in Term and Pre-term Neonates and Infants up to 3 Months of Age

Phase 3

Completed

Conditions: Neonatal Sepsis

Interventions: Drug: Ceftobiprole medocaril

First Posted Date: 2023-05-12

Last Posted Date: 2024-12-20

Lead Sponsor: Basilea Pharmaceutica

Target Recruit Count: 9

Registration Number: NCT05856227

Locations: 🇵🇱
Szpital Uniwersytecki - Klinika Neonatologii, Wroclaw, Poland
🇸🇰
Univerzitna nemocnica Martin, Martin, Slovakia
🇺🇸
NorthShore University HealthSystem-Evanston Hospital, Evanston, Illinois, United States

and more 11 locations

Collection of Data of Ceftobiprole Treated Patients: Comparison of Patients With and Without Certain Diseases

Completed

Conditions: Renal Insufficiency
Hepatic Insufficiency
Immunosuppression

Interventions: Drug: Ceftobiprole medocaril

First Posted Date: 2019-11-20

Last Posted Date: 2023-07-07

Lead Sponsor: Advanz Pharma

Target Recruit Count: 428

Registration Number: NCT04170309

Locations: 🇮🇹
Ospedale Sant'Orsola Malpighi, Bologna, Italy
🇪🇸
Hospital Universitari MútuaTerrassa Planta 15, Barcelona, Spain
🇪🇸
Hospital La Moraleja, Madrid, Spain

and more 15 locations

Ceftobiprole in the Treatment of Pediatric Patients With Pneumonia

Phase 3

Completed

Conditions: Community-acquired Pneumonia (CAP)
Hospital-acquired Pneumonia (HAP)

Interventions: Drug: IV standard-of-care cephalosporin
Drug: ceftobiprole medocaril

First Posted Date: 2018-02-20

Last Posted Date: 2023-05-12

Lead Sponsor: Basilea Pharmaceutica

Target Recruit Count: 138

Registration Number: NCT03439124

Locations: 🇭🇺
Bekes County Central Hospital, Gyula, Hungary
🇷🇴
Sf. Maria" Children's Emergency Clinical Hospital, Iaşi, Romania
🇭🇺
Fejer County St. Gyorgy University Teaching Hospital, Szekesfehervar, Hungary

and more 16 locations

Open and Exploratory Trial to Investigate the Pharmacokinetic of Ceftobiprole Medocaril in Patients With CSF Device

Phase 2

Completed

Conditions: Inflamed Meninges
Ventriculitis
Suspected Meningitis

First Posted Date: 2017-10-23

Last Posted Date: 2020-09-16

Lead Sponsor: Centre Hospitalier Universitaire Dijon

Target Recruit Count: 5

Registration Number: NCT03317093

Locations: 🇫🇷
CHU Dijon Bourgogne, Dijon, France

Ceftobiprole in the Treatment of Patients With Staphylococcus Aureus Bacteremia

Phase 3

Completed

Conditions: Staphylococcus Aureus Bacteremia

Interventions: Drug: Ceftobiprole medocaril
Drug: Daptomycin

First Posted Date: 2017-05-03

Last Posted Date: 2023-11-08

Lead Sponsor: Basilea Pharmaceutica

Target Recruit Count: 390

Registration Number: NCT03138733

Locations: 🇺🇸
Remington Davis Inc., Columbus, Ohio, United States
🇮🇹
Giuliano Isontina University Health Authority, Trieste, Italy
🇮🇱
The Baruch Padeh Medical Center, Poriyya 'Illit, Israel

and more 57 locations

Ceftobiprole in the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infections

Phase 3

Completed

Conditions: Acute Bacterial Skin and Skin Structure Infections

Interventions: Drug: vancomycin+aztreonam
Drug: ceftobiprole medocaril

First Posted Date: 2017-05-02

Last Posted Date: 2023-05-12

Lead Sponsor: Basilea Pharmaceutica

Target Recruit Count: 679

Registration Number: NCT03137173

Locations: 🇺🇸
Physician Alliance Research Center, Anaheim, California, United States
🇺🇸
Central Valley Research LLC, Fresno, California, United States
🇺🇸
L&C Professional Medical Research Institute, Miami, Florida, United States

and more 29 locations

Pharmacokinetics and Safety of Ceftobiprole in Neonates and Infants up to 3 Months Treated With Systemic Antibiotics

Phase 1

Terminated

Conditions: Bacterial Infections

Interventions: Drug: Ceftobiprole medocaril

First Posted Date: 2015-08-19

Last Posted Date: 2023-06-05

Lead Sponsor: Basilea Pharmaceutica

Target Recruit Count: 15

Registration Number: NCT02527681

Locations: 🇱🇹
Vilnius University Children's Hospital, Vilnius, Lithuania
🇱🇻
Children Clinical University Hospital, Riga, Latvia
🇺🇸
Loma Linda University Medical Center, Loma Linda, California, United States

and more 11 locations

A Study of Ceftobiprole in Patients With Fever and Neutropenia.

Phase 3

Terminated

Conditions: Fever
Neutropenia
Gram-positive Bacterial Infections
Pseudomonas Infection

Interventions: Drug: Ceftobiprole Medocaril
Drug: Cefepime with or without vancomycin

First Posted Date: 2007-09-14

Last Posted Date: 2012-08-01

Lead Sponsor: Basilea Pharmaceutica

Target Recruit Count: 2

Registration Number: NCT00529282

Ceftobiprole in the Treatment of Hospitalized Patients With Staphylococcus Aureus Bacteremia

Phase 2

Withdrawn

Conditions: Bacteremia

First Posted Date: 2007-07-23

Last Posted Date: 2013-02-20

Lead Sponsor: Basilea Pharmaceutica

Registration Number: NCT00505258

Ceftobiprole in the Treatment of Patients With Community-Acquired Pneumonia

Phase 3

Completed

Conditions: Pneumonia

Interventions: Drug: Ceftriaxone with or without Linezolid
Drug: Ceftobiprole medocaril

First Posted Date: 2006-05-16

Last Posted Date: 2012-08-02

Lead Sponsor: Basilea Pharmaceutica

Target Recruit Count: 638

Registration Number: NCT00326287

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy